

Corporate Action Notice



October 1, 2013

CUSIP Merge

Fubon Financial Holdings Co., Ltd.
144A CUSIP: 359515103/DR ISIN US3595151032
Reg S CUSIP: 359515202/DR ISIN US3595152022
DR Ticker Symbol: FBND
Ratio (DRs:Underlying Shares)1:10

BNY Mellon has been advised that Fubon Financial Holding Co., Ltd (the “Company”) will be delisting all the remaining outstanding Global Depositary Shares (“GDSs”) from the London Stock Exchange (“LSE”) effective on October 31, 2013 and simultaneously relist them on the Luxembourg Stock Exchange (“LuxSE”).

As of **October 31, 2013**, kindly merge the LSE listed 144A (CUSIP: 359515103) & Regulation S (CUSIP: 359515202) GDR facilities with the LuxSE listed 144A (CUSIP: 359515301) & Regulation S (CUSIP: 359515400) GDR facilities.

The following are the pertinent details:

London Stock Exchange

144A CUSIP: 359515103
Reg S CUSIP: 359515202

Luxembourg Stock Exchange

144A CUSIP: 359515301
Reg S CUSIP: 359515400

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New York

Melissa Sobolewski/Ravi Davis
+1 212 815-2267
Adrdesk@bnymellon.com

London

Damon Rowan
Vice President
+44 207 964 6527
damon.rowan@bnymellon.com

Hong Kong

Herston Powers
Vice President
+852 2 840 9868
Herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon may also transact with affiliates and dealers. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.